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E-mail: jlpesq@icb.ufmg.brTo assess the importance of carbohydrate moieties to the anti-
angiogenic activity of plasminogen fragments, we cloned the frag-
ment corresponding to amino acids Val79 to Thr346 (Kint3–4) that
presents the three glycosylation sites. The activity of glycosylated
and unglycosylated Kint3–4 was tested in murine sponge implant
model. We observed a significant decrease in the neovasculariza-
tion on the sponge after treatment with Kint3–4 by histological
examination and determination of the hemoglobin levels. The
effects were more intense with the glycosylated than the
unglycosylated protein. 99mTechnecium-labeled red blood cells
confirmed the inhibition of cell infiltration in the implanted
sponge. Studies using melanoma B16F1 implanted in a mouse
demonstrated that treatment with glycosylated Kint3–4
(0.15 nmol ⁄ 48 h) during 14 days suppresses tumor growth by
80%. The vascular endothelial growth factor mRNA levels on the
tumor were reduced after treatment. Kint3–4 is a potent plasmino-
gen fragment that has been found to inhibit tumor growth.
(Cancer Sci 2010; 101: 453–459)
T he vasculature is an important organ. Angiogenesis, the for-mation of new blood vessels from pre-existing capillaries,
is a fundamental and complex process involved in reproduction,
cellular development, and pathological events, such as inflam-
mation, diabetic retinopathy, endometriosis, adiposity, and
cancer.(1,2) During tumor growth and chronic inflammation, neo-
vascularization is required for the provision of nutrients and
oxygen and to mobilize host cells, such as leukocytes.(3,4) The
new vascular network demands an extensive interplay between
cells, soluble factors, and extracellular components, and is
tightly regulated by the expression of angiogenic and angiostatic
factors.(5,6) A wide range of molecules mediates angiogenesis by
acting directly or indirectly on endothelial cells via accessory
cells, such as polymorphonuclear leukocytes.(7–9) Among these
molecules are fragments of the plasmatic glycoprotein plasmino-
gen, which have different angiostatic activity. Plasminogen pre-
sents five segments that, because of their specific structure, were
designated as kringles (K1–K5). The antiproliferative activity of
plasminogen is shared by K1, K2, K3, and K4 being the most
potent angiostatin (K1–4 corresponding to amino acids Cys84–
Cys435), followed by K2–3.(10,11) The sequence numbering of
plasminogen starts with Glu1 of the mature protein or Glu20 for
human plasminogen when including signal peptide. K2 and K3
individually or in combination exhibit weak activity when com-
pared with K2–3, and a combination of K1–3 and K4 resulted in
the same activity level of K1–4.(11) It was also observed that the
most potent inhibitor of endothelial cell angiogenesis of is K1–3
(amino acids Cys84–Cys333 of plasminogen).(12) These results
show that proteolytic processing with the exposure of anti-
angiogenic sites, kringle conformation, interkringle interaction,
and carbohydrate moieties can alter efficiency and function.
Despite the anti-angiogenic activity of kringles, the importancedoi: 10.1111/j.1349-7006.2009.01403.x
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Pichia pastoris (P. pastoris) potently inhibited Lewis lung can-
cer and a B16–BL6 experimental metastasis model at a similar
potency of angiostatin and K1–3 expressed in Chinese hamster
ovary (CHO) cells.(12) The half-life of proteins expressed in P.
pastoris was sevenfold lower than those expressed in CHO.(12)
The authors attributed this effect upon half-life to any mamma-
lian processing advantage, such as glycosylation. In mice, the
endogenous angiostatin has a long half-life in circulation
(greater than 2 days), but the native human angiostatin has a
considerably shorter half-life of 4 h.(13) There is some contro-
versy in the literature regarding the capacity of P. pastoris to
modify a protein by glycosylation. While some authors verified
that most proteins are modified by N-linked glycosylation of the
high-mannose type, and virtually none are modified by O-linked
glycosylation,(14) others found that the major products are
O-linked mannose, and in the case of plasminogen, only a very
small quantity of N-linked oligosaccharides is present on
Asn289.(15) The present study was developed to address the
importance of carbohydrates for the biological activity of plas-
minogen fragments. One recombinant protein, Kint3–4, was
produced using P. pastoris. Kint3–4 contains amino acids
Val79–Thr346 and the three glycosylation sites of plasminogen.
Kint3–4 corresponds to the K1–3 fragment of human plasmino-
gen extended 13 amino acids in the direction of K4. In addition,
the protein presents fusion between Val79 and eight amino acids
(EAEAYVEF) from the AOX1 signal peptide. The angiostatic
activity of glycosylated and N-deglycosylated Kint3–4 was
investigated by determination of its effect upon tumor growth
and the inflammatory processes. Our results show that this C-ter-
minal extension, with the inclusion of the third carbohydrate
branch, improved the angiostatic activity and the half-life of the
recombinant protein when compared to the potency of K1–3
expressed in CHO.(12) The removal of N-linked carbohydrates
produced a much less efficient protein regarding capacity to
inhibit tumor growth and vascularization.
Materials and Methods
Animals. Eight-week-old, male C-57 mice (25–30 g) were
obtained from Animal Facilities of Federal University of Minas
Gerais (Belo Horizonte, Brazil). After sponge (or tumor)
implantation, the animals were maintained in individual cages
with food ⁄water ad libitum and in a controlled environment
(temperature and humidity). The experiments were done within
the guidelines established by the Brazilian College for Animal
Experimentation and by the local animal ethics committee.
B16F1 murine melanoma cells were from Ludwig Cancer
Research Institute (Sa˜o Paulo, Brazil).Cancer Sci | February 2010 | vol. 101 | no. 2 | 453–459
Cloning and transformation of Pichia pastoris. The fragment
encoding amino acids 79–346 of human plasminogen was
amplified from a cDNA library (Helica Biosystems, Helica,
Fullerton, CA, USA) using the primers GAATTCGTGTA
TCTCTCAGAGTGC and GCGGCCGCTTATGTGGGAGCCA
ATTG. The polymerase chain reaction (PCR) product was
cloned into pGEM-T (Promega, Madison, WI, USA) and
subcloned into pPIC9 (Invitrogen, Carlsbad, CA, USA) at the
EcoRI and NotI sites. pPIC9 containing the insert was linearized
by using BglII and the product was fused to transform the
P. pastoris strain SMD1165. Positive clones were identified by
replica plating of colonies in methanol.
Fermentation and purification. Positive clones were grown
into a 1-L flask containing 150 mL of yeast extract-peptone-
dextrose (YPD) medium. The samples were incubated at 30C,
240 rpm for 14 h. At optical density 2–6, the entire volume of
inoculum was transferred to a 14-L fermentor vessel (Bioflo
110; New Brunswick Scientific, Edison, NJ, USA) containing
3 L basal salt medium plus 4.4 mL ⁄L PTM1 trace metal solu-
tion and glycerol (40 g ⁄L).(16) The temperature was controlled
at 30C. The dissolved oxygen set point was 30%, and pH was
set at 5 and automatically adjusted with 7% ammonium hydrox-
ide. After 20 h fermentation, the glycerol-fed batch process was
initiated. The feeding medium consisted of 50% glycerol supple-
mented with 12 mL ⁄L trace metal solution. The feed rate was
24 mL ⁄L ⁄h (16) until the biomass reached 200 g ⁄L when the
induction phase was started. The induction medium consisted of
100% methanol supplemented with 12 mL ⁄L trace metal solu-
tion. The feeding was divided into three stages: 24-h induction
with 1 mL ⁄L ⁄h; 24–48-h induction with 2 mL ⁄L ⁄h; and 48–72-h
induction with 3 mL ⁄L ⁄ h. The recombinant protein was purified
by a process involving tangential filtration at the first step in a
hollow-fiber system using a 5-kDa cut-off membrane to separate
low molecular mass contaminants. The protein from the hollow-
fiber system was loaded in a gel filtration column (Sephadex
G100, 2.5 · 60 cm; Pharmacia, Upsala, Sweden) eluted with
0.1 M sodium phosphate buffer, pH 7.0. Partially-purified
recombinant Kint3–4 (300 lg) was loaded on a Sephasil (C8)
reverse-phase column (Pharmacia Biotech, Pharmacia, Upsala,
Sweden) eluted with a linear gradient from 0% to 100% acetoni-
trile containing 0.1% trifluoroacetic acid (TFA).
Deglycosylation. The tubes containing the protein eluted from
the reverse-phase column were dried and then resuspended into
20 lL water. Ten micrograms of protein were solubilized in
20 lL denatured solution (5% sodium dodecyl sulfate [SDS]
and 10% b-mercaptoethanol) and boiled for 10 min. After boil-
ing, 1 lL of 50 mM sodium phosphate buffer (pH 7.5), 1 lL of
10% Nonidet P-40, and 1 lL of 500 U peptide-N-glycosidase F
(PNGase F; New England Biolabs, Ipswich, MA, USA) were
added and incubated at 37C for 24 h. The product of incubation
was loaded on 10% SDS–polyacrylamide gel electrophoresis.
For the biological assays, the deglycosylated protein was
previously submitted to a filtration process through a 10-kDa
membrane (Amicon; Millipore, Billerica, MA, USA) to remove
carbohydrates.
Angiogenesis in sponge disc implants. Angiogenesis was indi-
rectly determined by the sponge implant model in mice.(17)
Polyurethane sponge discs (Vitafoam, London, UK), 8 mm in
diameter and 5 mm thick, were used as the matrix for fibrovas-
cular tissue growth. The sponge discs were sterilized overnight
in 70% ethanol and by boiling in distilled water for 15 min
before the implantation. The animals were anesthetized by an
intraperitoneal injection of 2.5% tribromoethanol (Sigma Chem-
ical, St Louis, MO, USA) 1 mL ⁄100 g body weight. The sponge
discs were aseptically implanted into a subcutaneous pouch. The
animals with the implant were randomly divided into two groups
(n = 6 each group). Treatment was initiated 24 h after the
implantation with subcutaneous daily injections of purified454Kint3–4 (0.5, 5, or 50 lg per animal per day) or deglycosylated
Kint3–4 (0.5, 5, or 50 lg per animal per day). The control group
received daily injections of 100 lL of 0.9% saline. On day 11
from the initiation of treatment (10 doses), the implanted mice
were anesthetized by an intraperitoneal injection of tribromoeth-
anol and killed by cervical dislocation. The sponge was
removed, dissected from the adherent tissue, weighed, and
homogenized for hemoglobin quantitation. Alternatively, the
sponges were analyzed for histological assessment.
Histology. The sponge implants were fixed in 10% formalin
(n = 3, prepared in isotonic saline) and embedded in paraffin;
5 lm-thick sections were obtained. The sections were stained
with hematoxylin–eosin and examined under a light microscope.
Tumor growth. The B16F1 melanoma cells were cultivated in
RPMI-1640 medium with 5% fetal bovine serum. Cultures were
kept at 37C in a humidified, dark chamber (2.5% CO2). After
growth phase, the inoculum (5 · 105 cells) was prepared in sal-
ine and then injected subcutaneously into the mice. The treat-
ment began 24 h after tumor implantation. Groups of 20 mice
each were treated with three different doses of purified Kint3–4
(0.015 nmol [0.5 lg] ⁄48 h, 0.15 nmol [5 lg] ⁄48 h, or 1.5 nmol
[50 lg] ⁄48 h or purified deglycosylated Kint3–4 (0.47 nmol
[0.5 lg] ⁄ 48 h, 4.7 nmol [5 lg] ⁄48 h, or 47 nmol [50 lg] ⁄48 h)
or 50 lg protein from fermentation without methanol induction.
The samples were administered subcutaneously until day 14 (7
doses), and on day 15, the animals were killed and the tumor
removed and weighed. The control group received injections of
100 lL of 0.9% saline.
Hemoglobin measurement. Colorimetric. One-hundred milli-
grams of the sponge implant or tumor were excised, homo-
genized in 2 mL Drabkin reagent (Labtest, Lagoa Santa, MG,
Brazil), and centrifuged at 10 000g for 15 min. The supernatant
was filtered through a 0.22-lm filter (Millipore, Billerica, MA,
USA), and the hemoglobin in the sample was determined at
540 nm. The amount of hemoglobin was calculated from known
amounts used as standards assayed in parallel.(18,19) The results
were expressed as lg Hb ⁄mg of wet tissue.
99mTechnecium (Tc)-labeled red blood cells. The procedure used
was as previously described.(20) The heparinized blood of the
mice (2 mL) was incubated with 1 mL SnCl2 (2.4 lg ⁄mL) for
60 min at 37C, followed by incubation for 10 min at 37C with
0.5 mL of 99mTc (1 mCi). The solution was centrifuged for
10 min at 2500g and the pellet resuspended in 2 mL saline
(procedure repeated three times). 99mTc-labeled red blood cells
(250 lL) were injected into the caudal vein of the mice. After
5 min, the animals were killed by cervical dislocation, the
sponges removed, weighed, and gamma radiation was counted
(ANSR-Abbott, Chicago, IL, USA).
Myeloperoxidase activity. The quantification of neutrophil tis-
sue accumulation was indirectly determined by myeloperoxidase
(MPO) activity.(21) The reaction mixture (150 lL) contained
1.6 mM 3,3¢–5,5¢-tetramethylbenzidine (TMB; Sigma, St Louis,
MO, USA) dissolved in dimethylsulfoxide (Merck, Darmstadt,
Germany), 0.003% H2O2 dissolved in 0.05 M phosphate buffer
(0.5% HETAB, pH 5.4), and 25 lL supernatant from the tissue
sample. The reaction was run for 5 min at 37C in a 96 well mi-
croplate and was started by adding the supernatant and the TMB
solution. After that, H2O2 was re-added and the mixture was
incubated at 37C for 5 min. The reaction was stopped by add-
ing 100 lL of 4 M H2SO4 and the products were quantified at
450 nm. The neutrophil content was calculated from a standard
curve based on MPO activity expressed as absorbance increase
at 450 nm from 5% casein peritoneal-induced neutrophils
assayed in parallel. The results are expressed as the relative
number of neutrophils per milligram of wet tissue.
N-acetylglucosaminidase activity. Quantification of macro-
phage tissue accumulation was indirectly determined by N-acet-
ylglucosaminidase (NAG) activity.(21) The reaction mixturedoi: 10.1111/j.1349-7006.2009.01403.x
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Fig. 1. (a) Schematic drawing of plasminogen and
Kint3–4 molecules showing the kringles (K) and
the carbohydrates moieties ( ). EAEAYVEF, fused
sequence from the AOX1 signal peptide. (b), Partial
amino-terminal sequence of plasminogen and
recombinant Kint3–4. The amino acids Val79 and
Thr346 are identified.
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Fig. 2. Sodium dodecylsulfate–polyacrylamide gel electrophoresis
(10%) of Kint3–4 expressed by Pichia pastoris. Lane 1, standard
molecular weight; lane 2, purified recombinant Kint3–4; lane 3,
purified recombinant Kint3–4 after digestion with peptide-N-
glycosidase F.(200 lL) contained 2.24 mM p-nitrophenyl-N-acetyl-b-D-gluco-
saminide (Sigma, USA) dissolved in citrate ⁄phosphate buffer
(0.1 M citric acid and 0.1 M Na2HPO4, pH adjusted to 4.5) and
100 lL supernatant from the tissue sample diluted in cit-
rate ⁄phosphate buffer. The reaction was run for 10 min at 37C.
The reaction was stopped by the addition of 100 lL of 0.2 M
glycine buffer (pH 10.6) and the products quantified at 405 nm.
The macrophage content was calculated from a standard curve
based on NAG activity expressed as the absorbance increase at
405 nm from 3% thioglycollate peritoneal-induced macrophages
assayed in parallel. The results are expressed in relative number
of macrophages per milligram of wet tissue.
Vascular endothelial growth factor expression levels. Quantitative
real-time PCR (qPCR) was performed with an ABI Prism 7000
Sequence Detection System (Applied Biosystems, Framingham,
MA, USA) using Sybr Green detection. The final PCR mixture
contained 1.5 lL each of forward and reverse primers (final
concentration: 1.5 pmol each). b-Actin was used as an internal
control to normalize the RNA amount used in the assay.
The primers used were CGAGGCCCAGAGCAAGAGAG and
GATCTTCTCCATGTCGTCCC (for mouse b-actin ampliconSantos et al.target of 87 bp), and AGTACATCTTCAAGCCGTCCTGTG
and TCTGACGTGGGCACGCACTCC (for vascular endothelial
growth factor [VEGF] amplicon target of 87 bp), 2 lL cDNA
(4 lg), 10 lL SYBR PCR mix, and 5 lL pure PCR water in a
20 lL final volume. The reaction took place under universal
cycling conditions, as specified by ABI (2 min at 50C, 10 min
at 95C, 40 cycles of 15 s at 95C, and 1 min at 60C).
Cycle threshold (CT) values were determined by automated
threshold analysis with ABI Prism version 1.0 software
(Applied Biosystems). The amplification efficiencies were deter-
mined by the slope of the dilution curve and linear regression
(r2) values. The expression level values of VEGF cDNA were
given in nanograms using the CT values of the standard curve
dilution.
Statistical analysis. Results are presented as mean ± SEM.
Comparisons between groups were carried out using Student’s
t-test for unpaired data. For three or more groups, comparisons
were carried out using one-way ANOVA, and differences
between groups were assessed using an appropriate post-test
test (as indicated). A P-value less than 0.05 was considered
significant.
Results
Protein expression, sequencing and deglycosylation. The frag-
ment of human plasminogen Kint3–4 (Fig. 1a) was expressed at
very high levels (200 mg ⁄L) by methylotrophic yeast P. pasto-
ris. N-terminal sequencing of Kint3–4 at the N-terminus showed
fusion between Val79 and the eight amino acids (EAEAYVEF)
from the AOX1 signal peptide (Fig. 1b).
Kint3–4 was purified and presented a molecular mass of
34 kDa. To evaluate the importance of glycosylation in Kint3–4
activity, Kint3–4 was digested with PNGase F, which is specific
for N-linked carbohydrates. After deglycosylation, carbo-
hydrates were removed by ultra filtration through a 10-kDa
membrane (Amicon; Millipore, Billerica, MA, USA). Degly-
cosylation caused the Mr 34 kDa band to migrate at Mr 32 kDa
(Fig. 2).
Inflammatory angiogenesis in sponge implants. Angiogenesis
and leukocyte influx was evaluated at day 11 after the beginning
of treatment. The histological examination of the sponge sec-
tions showed decreased neovascularization when the animals
were treated with glycosylated Kint3–4 at 50 lg ⁄day compared
to treatment with saline (Fig. 3). The vascularization level after
treatment with 5 lg ⁄day was not different to that observed for
the control (data not shown). Neovascularization was also mea-
sured by evaluating the amount of hemoglobin within theCancer Sci | February 2010 | vol. 101 | no. 2 | 455
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(a) (b)
(c) (d)
Fig. 3. Stained histological sections of implanted
sponge evaluated on day 11 after the beginning of
the treatment of mice with 5 lg ⁄ day glycosylated
Kint3–4 (b,d, n = 3) and the control (a,c, n = 3)
show the fibrovascular tissue infiltration pattern.
Magnification ·40 (a,b) and ·20 (c,d).
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Fig. 4. Angiogenesis level in implanted sponge evaluated on day 11
after the beginning of the treatment with Kint3–4 (glycosylated or
unglycosylated) or saline (S, control). Unglycosylated Kint3–4 at doses
5 (D5) or 50 (D50) lg ⁄ day; NI, non-induced fermentation; glycosylated
Kint3–4 at doses 0.5 (K0.5), 5 (K5) or 50 (K50) lg ⁄ day. (a) Hemoglobin
levels determined colorimetrically and expressed as microgram per
milligram of wet weight of sponge. (b) 99mTechnecium-labeled red
blood cells determined by radioactivity. Results represent the
mean ± SEM of 5–7 animals for each group. *P < 0.05 vs control (C).
Cpm, counts per minute.
456sponge. There was a significant decrease (60%) in the hemo-
globin levels in the sponge of the animals treated with
0.5 lg ⁄day glycosylated Kint3–4, and at 5 lg ⁄ day the decrease
was approximately 80% (Fig. 4a). The effect of unglycosylated
Kint3–4 was significantly lower (Fig 4a). 99mTc-labeled red
blood cells confirmed the inhibition of cell infiltration by Kint3–4
(Fig. 4b).
Using MPO- and NAG-based assays, we observed a small
effect in the accumulation of neutrophils and macrophages in
the sponge (decrease of 20%–25%) with an injection of the
unglycosylated protein at a dose of 50 lg ⁄day (Fig 5). However,
the injection of glycosylated Kint3–4 at dose of 0.5 lg ⁄day or
5 lg ⁄day led to a significant decrease (50% or 70%, respec-
tively) in the accumulation of these cells (Fig. 5).
Tumor growth. Tumor mass was evaluated on day 15 after
the beginning of treatment. Saline administration or 5 lg ⁄ 48 h
protein from non-induced fermentation did not inhibit tumor
growth (Fig. 6). The administration of 50 lg ⁄ 48 h (1500
lg ⁄kg ⁄48 h) unglycosylated protein inhibited tumor growth by
30%. For the glycosylated protein, the administration of
4.4 nmol (5 lg) ⁄48 h (150 lg ⁄kg ⁄48 h) significantly inhibited
the growth of experimental melanoma B16F1 by more than 80%
as compared to the control (saline) (Fig. 6). The levels of VEGF
mRNA on the implanted tumor melanoma B16F1, determined
by real time PCR, decreased after treatment with Kint3–4. Stan-
dard curves ranging from 1 to 10)9 ng for both VEGF and
b-actin cDNA demonstrated high linearity (r2 = 0.990) with slopes
smaller than )2 and calculated efficiencies (E = –1 ⁄ slope) for
both amplification reactions of 100%. The expression levels of
the VEGF gene was given as absolute quantities of each VEGF
amplicon normalized by its respective absolute b-actin quantity
(ng of VEGF ⁄ng of b-actin). The results of the absolute mean
values are shown in Table 1. The qPCR detected was as low as
3.5 · 10)6 ng for VEGF cDNA in the tumor sample. The VEGF
expression was significantly lower (P < 0.05) in the tumor sam-
ple from the animals treated with 50 lg ⁄48 h of unglycosylated
Kint3–4 than in the samples from animals treated with saline
(1.94-fold lower than that of the control). However, treatment
with glycosylated Kint3–4 produced a more intense effect upon
tumor VEGF levels (K0.5: 2.04-fold lower than that of the con-
trol [P < 0.05]; K5: 4.17-fold lower than that of the control
[P < 0.01]). No significant differences of the VEGF expression
were observed in the tumor sample from the animals treated with
non-induced fermentation or with 5 lg ⁄48 h unglycosylated
Kint3–4.doi: 10.1111/j.1349-7006.2009.01403.x
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Fig. 5. Neutrophil (a) and macrophage (b) accumulation in the
sponge in day 11 after beginning of treatment with systemically-
injected Kint3–4 (glycosylated or unglycosylated) or saline (S, control).
Unglycosylated Kint3–4 at doses 5 (D5) or 50 (D50) lg ⁄ day; NI,
non-induced fermentation; glycosylated Kint3–4 at doses 0.5 (K0.5)
or 5 (K5) lg ⁄ day. The recruitment of neutrophils or macrophages
was evaluated by measuring myeloperoxidase and N-acetylgluco-
saminidase activities, respectively. Results represent the relative
number of neutrophils (·104) or macrophages (·104) per milligram of
wet tissue and are expressed by the mean ± SEM of 5–7 animals for
each group. *P < 0.01 vs control (saline) and **P < 0.05 vs control
(saline).
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Fig. 6. Tumor mass evaluated on day 15 after the beginning of the
treatment of animals with implanted melanoma. S, 0.9% saline;
unglycosylated Kint3–4 at doses 5 (D5) or 50 (D50) lg ⁄ 48 h; NI, non-
induced fermentation; glycosylated Kint3-4 at doses 0.5 (K0.5), 5 (K5)
or 50 (K50) lg ⁄ 48 h. Results represent mean ± SEM of eight animals
for each group. *P < 0.01 vs control (saline) and **P < 0.05 vs control
(saline).
Table 1. Levels of transcript absolute expression of vascular
endothelial growth factor (VEGF) from the tumor after treatment of
tumor-bearing mice normalized to the invariant housekeeping gene
b-actin
Sample VEGF (ng) b-Actin (ng) VEGF ⁄ b-actin
Saline 2.71 ± ·10)06 7.61 ± ·10)04 0.00356
NI 2.80 ± ·10)06 7.40 ± ·10)04 0.00378
D5 2.23 ± ·10)06 6.67 ± ·10)04 0.00334
D50 4.85 ± ·10)06 7.01 ± ·10)04 0.00692*
K0.5 5.67 ± ·10)06 7.82 ± ·10)04 0.00725*
K5 1.17 ± ·10)05 7.88 ± ·10)04 0.01480**
Values are mean for each sample group (n = 4). Levels of transcripts
determined in the tumor homogenate day 11 after the beginning of
the treatment with saline (S, control), unglycosylated Kint3–4 at
doses 5 (D5) or 50 (D50) lg ⁄ 48 h; NI, non-induced fermentation;
glycosylated Kint3–4 at doses 0.5 (K0.5) or 5 (K5) lg ⁄ 48 h. *P < 0.05 vs
control (saline) and **P < 0.01 vs control (saline).
Santos et al.Discussion
Since the early 1970s, when angiogenesis was recognized as a
therapeutic and interesting tool,(22) there was been a greater
increase in the knowledge of the pathways involved in this
complex process. (23) Today, there are many anti-angiogenic
substances undergoing clinical trials worldwide(24). Among
them is angiostatin, an internal fragment of plasminogen corre-
sponding to the first four kringles.(13) Recombinant angiostatin
systemically administrated at 1.5 mg ⁄ kg ⁄day has been found
to suppress the metastases of Lewis lung carcinoma, a low-
metastatic phenotype tumor in mice, and at a dose of
100 mg ⁄kg ⁄day, suppresses the growth of the primary tumor.(25)
At this dose, recombinant angiostatin administered daily has
also been found to inhibit the growth of B16 murine melanoma
by 90%.(26) However, such doses are very high to use in human
therapy. Anti-angiogenic protein therapy includes repeated
injections for long periods of treatment. As the production of
functional recombinant proteins has been proven to be difficult,
alternative approaches need to be developed in order to make
the anti-angiogenic therapy viable. Kint3–4 improve the effi-
ciency of anti-angiogenic therapy of plasminogen fragments and
represent potential viability to be used in clinical settings.
Our results showed that purified Kint3–4 at a lower dose
(0.15 mg ⁄kg ⁄48 h) acts on tumors and reduce the tumoral mass
by around 80%. Our results show also that N-deglycosylation of
Kint3–4 produced a much less active protein in its ability to
inhibit tumor growth and vascularization. The presence of the
three carbohydrate moieties can be important for total activity.
However, Kint3–4 is much more active than angiostatin, which
can also present the three carbohydrates moieties. We believe
two explanations are possible: (i) the glycosylation status as a
result of Pichia glycosylation and protein manipulation; and (ii)
the presence of the C-terminal segment of angiostatin that could
impair its interaction by altering folding and stability. Plasmino-
gen derived from plasma contains both O- and N-linked carbo-
hydrates.(27,28) The O-linked carbohydrate could occupy two
sites on plasminogens Ser249 and Thr346, and the N-linked car-
bohydrate could occupy a site on Asn289.(28) The presence of
glycosylation can alter the properties of proteins by altering
folding and stability, clearance rate, proteinase resistance, and
intrinsic functions, such as receptor binding.(29) It seems that
P. pastoris is able to modify expressed proteins with N- and
O-linked carbohydrates. It is possible that glycosylation at the
C-terminal end on Thr346 could act in such way to facilitate or
alter the receptor binding capacity, enhancing activity. However,
the glycosylation would also interfere with the half-life of the
protein. In our tumor experiments, Kint3–4 was injected at 48 h.Cancer Sci | February 2010 | vol. 101 | no. 2 | 457
Journal compilation ª 2009 Japanese Cancer Association
No claim to original US government works
The importance of glycosylation for plasminogen fragment
activity has already been described.(10,27–29) It was observed that
the in vivo effects of K1–3 are limited to their content of carbo-
hydrates. It was observed also that desialylated angiostatin was
ineffective as an inhibitor of tubulogenesis, and it was suggested
that the anti-angiogenic effect of angiostatin depends on the con-
tents of sialic acid.
The subcutaneous implantation of a sponge induces a chronic
granulomatous response, including intense angiogenesis and the
infiltration of inflammatory cells.(30) The vascularization levels
on the implanted sponge and in the tumors, assessed by the
amount of hemoglobin in the tissues, was significantly reduced,
as determined by two methods, colorimetric and by 99mTc-
labeled red blood cells. The sponge-implanted glycosylated K3–
4-treated group presented a significant decrease of fibrovascular
tissue growth and cellular accumulation, and a lower number of
congested blood vessels when compared with the control group.
Leucocytes, in particular, neutrophils and macrophages, are
the first cells recruited to local injury.(31) Macrophages medi-
ate angiogenesis through the liberation of substances that act
on differentiation, migration, or proliferation of cells, such as
growth factors, cytokines, prostaglandins, and proteolytic
enzymes.(32,33) Our results showed a significant decrease in mac-
rophage infiltration, that could have mediated the angiostatic
effect of K3–4. Angiostatins inhibit neutrophil recruitment.(34)
Neutrophils express ATP synthase and angiomotin,(35,36) two
angiostatin-receptors that could mediate the effects of Kint3–4458on these cells. Our data showed an inhibition on neutrophil infil-
tration on the sponge by systemic injection of Kint3–4.
Interestingly, 14 days post-implantation of the melanoma cells,
the mortality rate was 50% for the control group, and only one
death occurred for the Kint3–4-treated group (n = 20). The treat-
ment protected the animals against this kind of tumor that specifi-
cally presents resistance against drugs, radiotherapy, and a high
incidence of metastasis.(37) It was demonstrated that some lines of
melanoma cells express the integrin cell adhesion receptor avb3
on their surface.(38) Cross-talking between VEGF, the major
angiogenic growth factor, and avb3 seems to be a critical factor in
the regulation of angiogenesis and tumor development.(39) It is
probable that one of the mechanisms of action of Kint3–4
involves this integrin, since a significant reduction in the VEGF
expression levels was observed after treatment with Kint3–4.
In the present study, we provide evidence that the presence of
carbohydrate moieties are of functional importance for the activ-
ity of angiostatin analogs. Furthermore, the VEGF expression
seems to be an important mechanism in this process. These
results expand the current understanding of how angiostatin ho-
mologs can interfere with tumor growth, promoting the inhibi-
tion of tumor angiogenesis.
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